Literature DB >> 16769811

Bone morphogenetic protein signaling and growth suppression in colon cancer.

Stayce E Beck1, Barbara H Jung, Antonio Fiorino, Jessica Gomez, Eunice Del Rosario, Betty L Cabrera, Sherry C Huang, Jimmy Y C Chow, John M Carethers.   

Abstract

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta superfamily, which utilize BMP receptors and intracellular SMADs to transduce their signals to regulate cell differentiation, proliferation, and apoptosis. Because mutations in BMP receptor type IA (BMPRIA) and SMAD4 are found in the germline of patients with the colon cancer predisposition syndrome juvenile polyposis, and because the contribution of BMP in colon cancers is largely unknown, we examined colon cancer cells and tissues for evidence of BMP signaling and determined its growth effects. We determined the presence and functionality of BMPR1A by examining BMP-induced phosphorylation and nuclear translocation of SMAD1; transcriptional activity via a BMP-specific luciferase reporter; and growth characteristics by cell cycle analysis, cell growth, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide metabolic assays. These assays were also performed after transfection with a dominant negative (DN) BMPR1A construct. In SMAD4-null SW480 cells, we examined BMP effects on cellular wound assays as well as BMP-induced transcription in the presence of transfected SMAD4. We also determined the expression of BMPR1A, BMP ligands, and phospho-SMAD1 in primary human colon cancer specimens. We found intact BMP signaling and modest growth suppression in HCT116 and two derivative cell lines and, surprisingly, growth suppression in SMAD4-null SW480 cells. BMP-induced SMAD signaling and BMPR1A-mediated growth suppression were reversed with DN BMPR1A transfection. BMP2 slowed wound closure, and transfection of SMAD4 into SW480 cells did not change BMP-specific transcriptional activity over controls due to receptor stimulation by endogenously produced ligand. We found no cell cycle alterations with BMP treatment in the HCT116 and derivative cell lines, but there was an increased G1 fraction in SW480 cells that was not due to increased p21 transcription. In human colon cancer specimens, BMP2 and BMP7 ligands, BMPRIA, and phospho-SMAD1 were expressed. In conclusion, BMP signaling is intact and growth suppressive in human colon cancer cells. In addition to SMADs, BMP may utilize SMAD4-independent pathways for growth suppression in colon cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769811      PMCID: PMC4138725          DOI: 10.1152/ajpgi.00482.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  38 in total

1.  The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase.

Authors:  M Kretzschmar; F Liu; A Hata; J Doody; J Massagué
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

2.  Mutations in the SMAD4/DPC4 gene in juvenile polyposis.

Authors:  J R Howe; S Roth; J C Ringold; R W Summers; H J Järvinen; P Sistonen; I P Tomlinson; R S Houlston; S Bevan; F A Mitros; E M Stone; L A Aaltonen
Journal:  Science       Date:  1998-05-15       Impact factor: 47.728

3.  Gene expression profiles in normal and cancer cells.

Authors:  L Zhang; W Zhou; V E Velculescu; S E Kern; R H Hruban; S R Hamilton; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1997-05-23       Impact factor: 47.728

Review 4.  Tumor suppressor activity of the TGF-beta pathway in human cancers.

Authors:  S D Markowitz; A B Roberts
Journal:  Cytokine Growth Factor Rev       Date:  1996-06       Impact factor: 7.638

5.  Cloning and characterization of a human type II receptor for bone morphogenetic proteins.

Authors:  B L Rosenzweig; T Imamura; T Okadome; G N Cox; H Yamashita; P ten Dijke; C H Heldin; K Miyazono
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

6.  DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.

Authors:  S A Hahn; M Schutte; A T Hoque; C A Moskaluk; L T da Costa; E Rozenblum; C L Weinstein; A Fischer; C J Yeo; R H Hruban; S E Kern
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

7.  Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma.

Authors:  C A Moskaluk; R H Hruban; M Schutte; A S Lietman; T Smyrk; L Fusaro; R Fusaro; J Lynch; C J Yeo; C E Jackson; H T Lynch; S E Kern
Journal:  Diagn Mol Pathol       Date:  1997-04

8.  Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs.

Authors:  F Liu; F Ventura; J Doody; J Massagué
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

9.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.

Authors:  W M Grady; A Rajput; L Myeroff; D F Liu; K Kwon; J Willis; S Markowitz
Journal:  Cancer Res       Date:  1998-07-15       Impact factor: 12.701

10.  Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.

Authors:  H Yamashita; P ten Dijke; D Huylebroeck; T K Sampath; M Andries; J C Smith; C H Heldin; K Miyazono
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

View more
  50 in total

Review 1.  The intestinal stem cell.

Authors:  Luis A Chia; Calvin J Kuo
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  GRG Profiles: John M. Carethers.

Authors:  John M Carethers
Journal:  Dig Dis Sci       Date:  2016-06       Impact factor: 3.199

3.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

4.  Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines.

Authors:  Eva-Maria Duerr; Yusuke Mizukami; Kentaro Moriichi; Manish Gala; Won-Seok Jo; Hirotoshi Kikuchi; Ramnik J Xavier; Daniel C Chung
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-01       Impact factor: 4.052

5.  Anti-inflammatory activity of bone morphogenetic protein signaling pathways in stomachs of mice.

Authors:  Hidehiko Takabayashi; Masahiko Shinohara; Maria Mao; Piangwarin Phaosawasdi; Mohamad El-Zaatari; Min Zhang; Tuo Ji; Kathryn A Eaton; Duyen Dang; John Kao; Andrea Todisco
Journal:  Gastroenterology       Date:  2014-04-18       Impact factor: 22.682

Review 6.  The Yin and Yang of bone morphogenetic proteins in cancer.

Authors:  Ashok Singh; Rebecca J Morris
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-04       Impact factor: 7.638

7.  Regulation and function of bone morphogenetic protein signaling in colonic injury and inflammation.

Authors:  Tuo Ji; Hidehiko Takabayashi; Maria Mao; Xu Han; Xiang Xue; Jennifer C Brazil; Kathryn A Eaton; Yatrik M Shah; Andrea Todisco
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-17       Impact factor: 4.052

8.  Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

Authors:  George S Karagiannis; Ann Treacy; David Messenger; Andrea Grin; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2014-04-19       Impact factor: 6.603

Review 9.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Authors:  Pawina Jiramongkolchai; Philip Owens; Charles C Hong
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

Review 10.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Authors:  John M Carethers; Barbara H Jung
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.